Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Key Stats

• Today's Range: $1.42 to $1.50
• 50-Day Range: $1.43 to $1.78
• 52-Week Range: $1.13 to $2.66
• Volume: 150,805 shs
• Average Volume: 202,675 shs
• Market Capitalization: $129.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 40% of companies evaluated by MarketBeat, and ranked 694th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Compugen has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.66% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Compugen has recently decreased by 2.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.66% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Compugen has recently decreased by 2.19%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Compugen has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

Search Interest

Only 3 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

Only 12.22% of the stock of Compugen is held by institutions.

CGEN Stock Analysis - Frequently Asked Questions

How have CGEN shares performed this year?

Compugen's stock was trading at $1.53 on January 1st, 2025. Since then, CGEN shares have decreased by 5.2% and is now trading at $1.45.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, August, 6th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biotechnology company earned $1.26 million during the quarter, compared to the consensus estimate of $3.95 million. Compugen had a negative net margin of 87.45% and a negative trailing twelve-month return on equity of 34.77%.
Read the conference call transcript.

Who are Compugen's major shareholders?

Top institutional investors of Compugen include ARK Investment Management LLC (1.20%), Taylor Frigon Capital Management LLC (1.11%), Jane Street Group LLC (0.44%) and Rothschild Investment LLC (0.20%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 70
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +175.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.23 million
• Net Margins: -87.45%
• Pretax Margin: -67.03%
• Return on Equity: -34.77%
• Return on Assets: -16.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.74
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $27.86 million
• Price / Sales: 4.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 2.59

Miscellaneous

• Outstanding Shares: 89,240,000
• Free Float: 80,759,000
• Market Cap: $129.40 million
• Optionable: Optionable
• Beta: 2.61